Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France. - Centre d'Immunologie et des Maladies Infectieuses
Article Dans Une Revue Journal of Infection Année : 2022

Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France.

Résumé

OBJECTIVES: Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes. The primary aim of the study was to assess the impact of the implementation of rapid diagnostic tests on HR-TB treatment in France. METHODS: We designed a retrospective multicentre study including consecutive HR-TB patients diagnosed in 2016 and 2017. Implementation of a molecular assay detecting isoniazid resistance directly on a clinical sample was recorded. The association between early implementation of such assays and adequate treatment was assessed by a multivariable Cox proportional hazards model. RESULTS: Overall, 99 HR-TB patients were included from 20 University Hospitals. Among all smear-positive HR-TB patients, only 26% beneficiated from early molecular HR detection. This detection was independently associated with shorter time to adequate treatment (HR~=~2.0 [1.1-3.8], p~=~0.03). CONCLUSION: In our study, molecular detection of HR on an initial sample was independently associated with earlier treatment adaptation.
Fichier principal
Vignette du fichier
S0163445322003061.pdf (399.85 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03697160 , version 1 (22-07-2024)

Licence

Identifiants

Citer

Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, et al.. Molecular Detection of Isoniazid Monoresistance Improves Tuberculosis Treatment: A Retrospective Cohort in France.. Journal of Infection, 2022, 85 (1), pp.24--30. ⟨10.1016/j.jinf.2022.05.017⟩. ⟨hal-03697160⟩
98 Consultations
17 Téléchargements

Altmetric

Partager

More